

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Clinica Cardiovascular de Guaynabo</p>	<p>In accordance with application dated September 9, 2016</p>	<p>4. Expiration Date: December 31, 2026</p>	
<p>2. P.O. Box 965 Guaynabo, PR 00970-0965</p>	<p>3. License number: 52-31182-01 is renewed in its entirety to read as follows:</p>	<p>5. Docket No.: 030-37326 Reference No.:</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any byproduct material identified in 10 CFR 35.100</p> <p>B. Any byproduct material identified in 10 CFR 35.200</p> <p>C. Any byproduct material identified in 10 CFR 35.300</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 500 millicuries total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.</p>

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at Calle Carazo #11, Guaynabo, Puerto Rico.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number


52-31182-01

Docket or Reference Number

030-37326

Amendment No. 4

11. The Radiation Safety Officer for this license is David Rhoe, M.S.
12. A. Licensed material shall only be used by, or under the supervision of:
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User(M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|--|-------------------------|
| Juan Fontanez Nieves, M.D. | 35.100; 35.200; I131 |
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.




**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
52-31182-01Docket or Reference Number
030-37326

Amendment No. 4

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated September 9, 2016 [ML16286A500]

B. Letter dated November 29, 2016 [ML16354A285]



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: December 19, 2016By: Robin Elliott
Robin Elliott
Region 1